We have shown that cell surface heparan sulfate serves as the initial receptor for both serotypes of herpes simplex virus (HSV). We found that virions could bind to heparin, a related glycosaminoglycan, and that heparin blocked virus adsorption. Agents known to bind to cell surface heparan sulfate blocked viral adsorption and infection. Enzymatic digestion of cell surface heparan sulfate but not of dermatan sulfate or chondroitin sulfate concomitantly reduced the binding of virus to the cells and rendered the cells resistant to infection. Although cell surface heparan sulfate was required for infection by HSV types 1 and 2, the two serotypes may bind to heparan sulfate with different affinities or may recognize different structural features of heparan sulfate. Consistent with their broad host ranges, the two HSV serotypes use as primary receptors ubiquitous cell surface components known to participate in interactions with the extracellular matrix and with other cell surfaces.
Recent work has confirmed earlier proposals about the pathway of herpes simplex virus (HSV) entry into a cell. Following attachment of the virion to the cell surface, the viral envelope fuses with the plasma membrane (16, 30, 33) and the viral capsid is released into the cytoplasm. The adsorption and penetration events probably require at least three of the seven envelope glycoproteins encoded by the viral genome (36) . Genetic evidence demonstrates that the glycoproteins designated gB, gD, and gH are required for virus entry into a cell, at least in part for steps occurring after the initial attachment of virions to the cells (3, 4, 11, 25, 26, 35) . Moreover, neutralizing monoclonal antibodies specific for each of these three glycoproteins can block viral penetration with little or no effect on virion adsorption to cells (16, 19, 20; A. 0. Fuller, R. Santos, and P. G. Spear, manuscript in preparation). The other four known glycoproteins are apparently dispensable for viral replication in cultured cells (12, 21, 27, 32) . That gD and gB are present in different morphologically distinct spikes projecting from the virion envelope (38) implies a requirement for multiple virion-cell surface interactions subsequent to adsorption in order for virion-cell fusion to occur. Cell surface molecules necessary for the initiation of HSV infection have not been identified until now. Glycosaminoglycans are long, polyanionic carbohydrate chains consisting of repeating disaccharide units. In proteoglycans, these polymers are covalently attached to a protein core. The glycosaminoglycan heparin has long been known to inhibit the infection of cultured cells by HSV but not by many other viruses (31, 39, 40) . The basis for this inhibition was not understood. Because heparan sulfate proteoglycans, which carry glycans similar to heparin, are present on the surface of most types of vertebrate cells, we explored the possibility that heparan sulfate serves as a receptor for HSV. We conclude that both HSV types 1 and 2 (HSV-1 and HSV-2) normally initiate infection by binding first to cell surface heparan sulfate. The probable necessity for subsequent receptor interactions at the cell surface is discussed.
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MATERIALS AND METHODS
Viruses and cells. HEp-2 cells were obtained from the American Type Culture Collection. Cells were passaged in Dulbecco modified Eagle (DME) medium supplemented with 10% fetal bovine serum. HSV-1(KOS) was kindly provided by Priscilla Schaffer of the Harvard Medical School, HSV-2(G) has been described previously (13) , and Sendai/RU virus was kindly provided by Robert Lamb of Northwestern University.
Virus purification. Virions purified as described by Spear and Roizman (37) (15 FCi/ml) , and incubated at 37°C for 48 h. Virus was harvested and purified from infected-cell lysates by centrifugation through dextran gradients (Dextran T10; Pharmacia). Titers were determined by plaquing on HEp-2 cells, and radioactivity was determined by liquid scintillation counting. Most virus preparations had titers of 108 to 109 PFU/ml and radioactivities of 106 to 107 cpm/ml. Just prior to use, virus was diluted 1:4 (vol/vol) in phosphate-buffered saline (PBS: 10 mM Na2HPO4, 1.5 mM KH2PO4, 140 mM NaCl, 2.5 mM KCl, 0.5 mM MgCl2, 1 mM CaCl2) and centrifuged in a Centricon-30 concentrator (Amicon), according to the manufacturer's directions, to remove most of the dextran.
Inhibitory agents and enzyme digestions. Heparin (Sigma), poly-L-lysine (Sigma), and platelet factor 4 (Sigma) were dissolved at the appropriate concentrations in PBS with or without purified virus. Heparitinase, heparinase, and chondroitin ABC lyase (ICN ImmunoBiologicals) digestions were done in PBS-0.1% glucose-0.1 to 1.0 mg of bovine serum albumin per ml-100 mM phenylmethylsulfonyl fluoride or 500 U of aprotinin per ml. Amounts used are expressed in conventional units (1 conventional unit = 6 mIU) per milliliter. None of these enzyme treatments caused any detachment of cells from the monolayers. Viral plaque assays. For viral plaque assays, untreated or enzyme-treated HEp-2 cells in 25-cm2 flasks were inoculated HSV BINDS INITIALLY TO CELL SURFACE HEPARAN SULFATE with virus in PBS supplemented with 0.1% glucose and, in some instances, containing one of the inhibitory agents to be tested. After a 30-min incubation, the viral inoculum was removed and the cells were overlaid with DME containing 1% heat-inactivated fetal bovine serum and 0.1% pooled human gamma globulin. Plaques were counted after 3 to 4 days. For Sendai virus plaquing, HEp-2 cells were inoculated with virus in DME containing 1% bovine serum albumin. Following incubation for 45 min at 37°C, the viral inoculum was removed and replaced with DME supplemented with 1% bovine serum albumin, 1 ,ug of acetylated trypsin (Sigma) per ml, and 0.7% SeaPlaque agarose (FMC Bioproducts). Plaques were counted after 2 days.
Binding of radiolabeled virus to cells. Confluent monolayers of HEp-2 cells in 24-well cluster dishes were pretreated for 15 min at 37°C with PBS containing 1% fetal bovine serum, 0.1% glucose, and bovine serum albumin (5 mg/ml) in order to block nonspecific virus adsorption. This pretreatment was omitted for the enzyme-treated cells. The cells were then inoculated with radiolabeled virions (about 107 PFU or 105 cpm) in 0.15 ml of PBS supplement with bovine serum albumin (1 to 2 mg/ml) and, in some instances, containing one of the inhibitors to be tested. After 30 min of adsorption at 37°C, the virus inoculum was removed and the cells were rinsed at least three times with PBS. Cells, along with any bound or penetrated virus, were lysed in PBS-1% sodium dodecyl sulfate (SDS)-1% Triton X-100. The lysates were then dissolved in Ecolume (ICN BioMedicals), and radioactivity was counted in a scintillation counter.
Affinity chromatography. One-milliliter columns of heparin-Sepharose (Pharmacia), Sepharose (Pharmacia), and polylysine-agarose (Pierce) were equilibrated with PBS. Virus samples were loaded in 1 ml of PBS, and the columns were then washed with 10 ml of PBS. Material flowing through the columns from the loading and washing procedures was pooled and assayed for infectivity and radioactivity.
Labeling of cell surface glycosaminoglycans. To (20 ,uCi/ml). After 30 min, the cells were rinsed with PBS and lysed in SDS sample buffer (10 mM sodium phosphate buffer [pH 7.0], 1% SDS, 0.1 M dithiothreitol, 10% glycerol, 0.001% bromophenol blue). The lysates were boiled for 15 min and then loaded on an 8.5% polyacrylamide-SDS slab gel (N-N'-diallyltartardiamide cross-linked). Following electrophoresis, the gels were fixed, soaked in Amplify (Amersham), dried, and exposed to film at -70°C.
Competition assay. For competition assays, relative particle numbers in labeled and unlabeled preparations of purified HSV-1 and HSV-2 were determined by quantitating relative amounts of the VP5 (capsid) protein. Equal volumes of the various viral preparations were electrophoresed by SDSpolyacrylamide gel electrophoresis (PAGE). Following silver staining, the gels were scanned by optical densitometry. Electron microscopy confirmed that in all virus preparations, about 85% of the virus particles were enveloped. To determine the amount of virus required to saturate the cell surface, increasing concentrations of [35S]methionine-labeled HSV-1(KOS) were adsorbed to confluent monolayers of HEp-2 cells in 96-well (round-bottomed) microtiter plates for 2 h at 4°C. The cells were washed with PBS, and the amount of radioactivity remaining associated with the cells was quantitated by lysing the cells and measuring radioactivity by liquid scintillation counting. Saturation of radiolabeled virus binding occurred at 2 x 109 PFU/ml. In the competition assay, cells in 96-well (round-bottomed) plates were inoculated at 4°C for 2 h with a constant saturating amount of radiolabeled virus (2.2 x 109 PFU/ml; about 670 PFU/cell) plus various amounts of competing unlabeled virus. Following several rinses of the cells, the cells and any associated virus were lysed in PBS-1% SDS-1% Triton X-100, and the radioactivity in the lysates was counted in a liquid scintillation counter.
RESULTS
Inhibitors of HSV adsorption and infection. We tested whether early events in HSV infection, in particular adsorption, could be inhibited by agents that should block the putative attachment of virus to heparan sulfate. The potential inhibitory agents tested were heparin, poly-L-lysine, and platelet factor 4. Heparin and poly-L-lysine should bind to polycations and polyanions, respectively, present on the surfaces of virions and cells. Platelet factor 4 is a small, slightly basic protein with specific affinity for glycosaminoglycans, especially heparin and heparan sulfate. Polybrene, a polycation, and protamine sulfate, a heparin antagonist, have previously been shown to reverse the effects of heparin as well as inhibit HSV infection when used alone (40) .
These agents were incubated with HEp-2 cells either immediately before or during exposure of the cells to purified HSV-1 strain KOS [HSV-1(KOS)] or HSV-2 strain G [HSV-2(G)]. Effects on plaque formation and on adsorption of radiolabeled virions to the cells were assessed. When plaque formation was monitored, replicate cultures of cells were incubated with agent immediately after the period of virus adsorption also in order to control for postadsorption effects on plaque formation. Figure 1 shows that heparin inhibited plaque formation, as previously reported, and also inhibited virion adsorption, but only when present during virus adsorption. Poly-L-lysine and platelet factor 4 also inhibited plaque formation and virion adsorption. In contrast to heparin, however, these agents had inhibitory effects whether they were incubated with cells before or during exposure of the cells to virus.
Inhibition of plaque formation by heparin and platelet factor 4 can be explained by inhibition of virus attachment to cells, whereas the inhibition of plaque formation by poly-L-lysine is only partly attributable to effects on virus adsorption (Fig.   1 ).
Interestingly, while both HSV serotypes were affected by these agents, HSV-1 adsorption and infection were less sensitive to inhibition by heparin but more sensitive to inhibition by platelet factor 4 in comparison with HSV-2 (note the difference in scale for the heparin dose). Furthermore, poly-L-lysine partially inhibited HSV-1 adsorption but had no significant effect on HSV-2 adsorption despite its marked effect on both HSV-1 and HSV-2 infectivity. Clearly, for both HSV-1 and HSV-2, poly-L-lysine inhibited a postadsorption step required for the initiation of infection, but only when poly-L-lysine was incubated with the cells before or during virus adsorption and not when added after virus adsorption. A full explanation of these results and differences between HSV-1 and HSV-2 will require knowledge of the chemical groups involved in initial and subsequent interactions of the virions with the cell surface.
Apolipoprotein B, whose binding to the low-density lipoprotein receptor is also inhibited by heparin and heparin antagonists (2, 18) , had no effect on HSV infectivity (data not shown).
Affinity chromatography. Affinity chromatography experiments showed that virions could bind to heparin but not to polylysine ( (Table 2) .
We treated HEp-2 cells with various concentrations of the three enzymes to assess their effects on the ability of the cells to adsorb virus and to become infected. Cells treated with chondroitin ABC lyase were indistinguishable from control cells in both assays (data not shown). Digestion with either heparitinase or heparinase before virus adsorption, but not after, resulted in reduced numbers of plaques on the treated cells and in reduced efficiency of virion adsorption (Fig. 2) . In contrast, heparitinase or heparinase pretreatment of HEp-2 cells had no effect on the infectivity of Sendai virus, which also enters cells by fusing with the plasma membrane, but after adsorption to sialic acid on specific cell surface gangliosides (7, 28) . In Heparinase (1) 68,000 48
Heparitinase (1) 64,000 33
Chondroitin lyase (2) (Fig. 4) . Heparinase-and heparitinase-treated cells could be infected but only at the highest concentrations of Heparitinase (u/ml) Heparinase (u/ml) virus used. (Fig. 5) .
tion period. The quantitation of PFU (solid lines) and adsorbed virions (dashed lines) was done as described in the legend in Fig. 1 .. heparan sulfate on the cell surface. Agents that can block this interaction effectively block HSV adsorption and infection. Heparin binds to virions, presumably occupying the sites necessary for attachment of virions to cell surface heparan sulfate. Platelet factor 4 blocks HSV adsorption and infection by modifying the cell. Presumably it binds to heparan sulfate and occupies sites to which virions normally bind. Enzymatic removal of heparan sulfate from the cell surface significantly reduced the efficiency with which the cells could be infected. This implies that heparan sulfate either is required for infectivity or greatly enhances the efficiency of infection. Although the virus selectively interacts with heparan sulfate, we cannot rule out low-efficiency interactions with other cell surface polyanions.
The results obtained with HEp-2 cells are probably generalizable to other cell types. Certainly, heparin has been tested for its ability to inhibit HSV infection of a variety of cell types, with uniformly positive results (39; unpublished results). Moreover, heparan sulfate in multiple forms is present on the surface of many cell types (22) . Besides being a constituent of the extracellular matrix, the proteoglycan can be intercalated into the plasma membrane via its protein moiety, with its glycosaminoglycan chains on the outside of the cell (23, 34) . Cell surface heparan sulfate is required for certain cell-cell and cell-substratum interactions (8, 9, 17, 24) .
Mutant derivatives of Chinese hamster ovary (CHO) cells have been isolated and shown to be deficient in various aspects of glycosaminoglycan synthesis (14) . Because the CHO cell line is one of the few cultured cell types that does not support HSV replication, it is not ideal for studies of HSV entry. Nevertheless, we have tested two mutant derivatives of the CHO cell line (kindly provided by J. Esko, University of Alabama) and found that radiolabeled HSV-1 and HSV-2 bound very poorly if at all to the mutant cells, whereas both bound efficiently to the parental wild-type CHO cells. The mutants tested lacked xylosyltransferase (CHO 745) or galactosyltransferase I (CHO 761) and were deficient in synthesis of all glycosaminoglycans (14, 15) . We are currently analyzing additional mutants with more selective defects in synthesis of specific classes of glycosaminoglycans.
Previous studies indicated that prior adsorption to cells of inactivated or mutant HSV-1 could inhibit subsequent infection with HSV-1 but not with HSV-2, suggesting that the two serotypes used different cell surface receptors or different pathways of entry (1, 41, 42) . The experiments reported here show that both HSV-1 and HSV-2 make their initial contact with cells through binding to heparan sulfate and that they compete with each other for this initial contact.
The differences previously observed for HSV-1 and HSV-2 entry may involve steps subsequent to initial attachment. Multiple interactions between the virion envelope and plasma membrane probably occur after attachment and prior to viral penetration by fusion of the virion envelope with the plasma membrane. The seven HSV glycoproteins, especially the three glycoproteins known to be required for HSV infectivity, may all participate in these interactions. Some of these HSV-1 and HSV-2 glycoproteins may have diverged sufficiently that the pathways of HSV-1 and HSV-2 entry diverge after the first step.
There are several compelling reasons for proposing that the interaction of HSV-1 or HSV-2 with heparan sulfate is only the first in a cascade of interactions culminating in fusion of the virion envelope with the plasma me`-brane.
First, both gB and gD are required for HSV penetration, but not necessarily for adsorption, and each is found in a different structure projecting from the virion envelope (3, 16, 19, 20, 25, 26,.35, 38 (9, 10) .
